Medartis Holding (MED) Stock Overview
A medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
MED Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medartis Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 88.20 |
| 52 Week High | CHF 97.50 |
| 52 Week Low | CHF 70.60 |
| Beta | 1.17 |
| 1 Month Change | -3.08% |
| 3 Month Change | 14.69% |
| 1 Year Change | 11.36% |
| 3 Year Change | 13.81% |
| 5 Year Change | -11.62% |
| Change since IPO | 42.35% |
Recent News & Updates
Narrative Update • Jun 23
MED: Award Recognition And Steady Assumptions Will Support Future Upside
The analyst price target for Medartis Holding has been trimmed slightly from CHF 95.97 to CHF 95.00, reflecting small updates to fair value inputs, discount rate, revenue growth, profit margin and future P/E assumptions cited by analysts. What's in the News Medartis Holding received the 2026 Swiss Medtech Award for its titanium implant systems, a recognition of its work in clinically focused product development and collaboration with surgeons.Narrative Update • Jun 05
MED: Stable Assumptions And Lower Discount Rate Will Support Future Upside
Analysts have kept their CHF 95.97 price target for Medartis Holding unchanged, citing consistent assumptions on fair value, revenue growth of 18.20% and a profit margin of 8.45%, along with only minor adjustments to the discount rate and future P/E inputs. What's in the News No recent company specific news for Medartis Holding is available from the listed sources.Narrative Update • Apr 28
MED: Slightly Higher Margins And Stable Outlook Will Support Future Upside
Analysts have kept their CHF price target for Medartis Holding broadly unchanged near CHF 96, citing slightly higher assumed revenue growth, a modestly stronger profit margin, and a marginally lower future P/E multiple in their refreshed models. Valuation Changes Fair Value: CHF 95.97 is unchanged in the refreshed model.Recent updates
Narrative Update • Jun 23
MED: Award Recognition And Steady Assumptions Will Support Future Upside
The analyst price target for Medartis Holding has been trimmed slightly from CHF 95.97 to CHF 95.00, reflecting small updates to fair value inputs, discount rate, revenue growth, profit margin and future P/E assumptions cited by analysts. What's in the News Medartis Holding received the 2026 Swiss Medtech Award for its titanium implant systems, a recognition of its work in clinically focused product development and collaboration with surgeons.Narrative Update • Jun 05
MED: Stable Assumptions And Lower Discount Rate Will Support Future Upside
Analysts have kept their CHF 95.97 price target for Medartis Holding unchanged, citing consistent assumptions on fair value, revenue growth of 18.20% and a profit margin of 8.45%, along with only minor adjustments to the discount rate and future P/E inputs. What's in the News No recent company specific news for Medartis Holding is available from the listed sources.Narrative Update • Apr 28
MED: Slightly Higher Margins And Stable Outlook Will Support Future Upside
Analysts have kept their CHF price target for Medartis Holding broadly unchanged near CHF 96, citing slightly higher assumed revenue growth, a modestly stronger profit margin, and a marginally lower future P/E multiple in their refreshed models. Valuation Changes Fair Value: CHF 95.97 is unchanged in the refreshed model.Narrative Update • Apr 13
MED: Slightly Higher Margins And Stable Outlook Will Support Future Upside
Analysts have kept their CHF price target for Medartis Holding broadly unchanged at around CHF 96, citing slightly higher estimates for revenue growth and profit margins and a marginally lower future P/E expectation. Valuation Changes Fair Value: CHF 95.97 remains unchanged, indicating no revision to the central value estimate.Narrative Update • Mar 29
MED: Higher P/E Assumptions Will Support A More Upbeat Forward Outlook
Analysts have trimmed their price target for Medartis Holding to around CHF 96 from roughly CHF 98, citing updated assumptions for slightly lower revenue growth, a reduced profit margin, and a higher future P/E multiple. Valuation Changes Fair Value: Trimmed slightly to CHF 95.97 from CHF 97.63, reflecting the updated model inputs.Narrative Update • Mar 12
MED: Stable Assumptions Will Support A More Upbeat Forward Outlook
Analysts have slightly adjusted their view on Medartis Holding, with the updated price target now aligned with a fair value estimate of CHF 97.63. This reflects minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions rather than any major shift in the investment case.Narrative Update • Feb 26
MED: Updated Assumptions Will Support A Balanced Yet Cautious Outlook
Analysts have slightly adjusted their CHF price target on Medartis Holding, reflecting updated assumptions that combine a similar fair value estimate with modest changes to the discount rate, expected revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: CHF 97.63 remains unchanged.Narrative Update • Feb 12
MED: CFO Succession And Recent Acquisitions Will Support A Stronger Outlook
Analysts have kept their CHF price target for Medartis Holding broadly unchanged, citing stable fair value assumptions, only minor tweaks to the discount rate and revenue growth outlook, and a P/E expectation that remains close to prior estimates. What's in the News Medartis Holding AG announced that Chief Financial Officer Dirk Kirsten plans to leave the company in the second half of 2026 to pursue new projects and responsibilities.Narrative Update • Jan 28
MED: CFO Transition And Acquisitions Will Shape A Measured Forward Outlook
Analysts have lifted their price target on Medartis Holding to CHF 97.63 from CHF 95.45, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margins and future P/E as the key drivers of the change. What's in the News Medartis Holding AG announced that Chief Financial Officer Dr Dirk Kirsten, who has served as an executive member since 2021, plans to leave the company in the second half of 2026 to take on new projects and responsibilities.Narrative Update • Jan 14
MED: Future CFO Transition And Acquisitions Will Shape Balanced Outlook
Analysts have increased their fair value estimate for Medartis Holding from €92.30 to €95.45, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News Medartis Holding plans a CFO transition, with current CFO Dr Dirk Kirsten intending to leave in the second half of 2026 to pursue new projects and responsibilities (Key Developments).Analysis Article • Dec 24
Is Now The Time To Look At Buying Medartis Holding AG (VTX:MED)?
While Medartis Holding AG ( VTX:MED ) might not have the largest market cap around , it led the SWX gainers with a...Analysis Article • Nov 27
Investors Still Waiting For A Pull Back In Medartis Holding AG (VTX:MED)
Medartis Holding AG's ( VTX:MED ) price-to-sales (or "P/S") ratio of 4.3x may not look like an appealing investment...Analysis Article • Nov 06
Estimating The Intrinsic Value Of Medartis Holding AG (VTX:MED)
Key Insights Medartis Holding's estimated fair value is CHF76.67 based on 2 Stage Free Cash Flow to Equity Current...Analysis Article • Sep 25
Medartis Holding (VTX:MED) Has A Rock Solid Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Aug 22
Earnings Update: Medartis Holding AG (VTX:MED) Just Reported And Analysts Are Trimming Their Forecasts
It's been a pretty great week for Medartis Holding AG ( VTX:MED ) shareholders, with its shares surging 11% to CHF83.10...Analysis Article • Aug 21
Investors Continue Waiting On Sidelines For Medartis Holding AG (VTX:MED)
With a median price-to-sales (or "P/S") ratio of close to 3.8x in the Medical Equipment industry in Switzerland, you...Analysis Article • Apr 13
Returns At Medartis Holding (VTX:MED) Appear To Be Weighed Down
If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...Analysis Article • Mar 26
We Think Medartis Holding's (VTX:MED) Robust Earnings Are Conservative
Medartis Holding AG ( VTX:MED ) recently posted some strong earnings, and the market responded positively. Our analysis...
New Narrative • Mar 23
New CEO And Keri Touch Launch Will Accelerate US And LATAM Expansion
The strategic initiatives under new leadership in the U.S. and LATAM, including product launches and acquisitions, aim to improve revenue and market share.Analysis Article • Mar 21
These 4 Measures Indicate That Medartis Holding (VTX:MED) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Jan 20
Even With A 29% Surge, Cautious Investors Are Not Rewarding Medartis Holding AG's (VTX:MED) Performance Completely
Medartis Holding AG ( VTX:MED ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...Analysis Article • Nov 27
A Piece Of The Puzzle Missing From Medartis Holding AG's (VTX:MED) Share Price
With a median price-to-sales (or "P/S") ratio of close to 3.8x in the Medical Equipment industry in Switzerland, you...Analysis Article • Nov 09
Medartis Holding (VTX:MED) Has A Rock Solid Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Aug 27
The Strong Earnings Posted By Medartis Holding (VTX:MED) Are A Good Indication Of The Strength Of The Business
Even though Medartis Holding AG's ( VTX:MED ) recent earnings release was robust, the market didn't seem to notice. Our...Analysis Article • Aug 21
Medartis Holding AG (VTX:MED) Doing What It Can To Lift Shares
It's not a stretch to say that Medartis Holding AG's ( VTX:MED ) price-to-sales (or "P/S") ratio of 4.2x right now...Analysis Article • May 10
When Should You Buy Medartis Holding AG (VTX:MED)?
While Medartis Holding AG ( VTX:MED ) might not have the largest market cap around , it saw a decent share price growth...Analysis Article • Apr 11
Shareholders Will Probably Not Have Any Issues With Medartis Holding AG's (VTX:MED) CEO Compensation
Key Insights Medartis Holding's Annual General Meeting to take place on 17th of April CEO Christoph Bronnimann's total...Analysis Article • Feb 14
The Returns On Capital At Medartis Holding (VTX:MED) Don't Inspire Confidence
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analysis Article • Oct 24
Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Analysis Article • Oct 03
Is Medartis Holding (VTX:MED) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Sep 06
Is Medartis Holding AG (VTX:MED) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Medartis Holding's estimated fair value is CHF68.50 based on 2 Stage Free Cash Flow to Equity Current...Analysis Article • Jun 21
Market Still Lacking Some Conviction On Medartis Holding AG (VTX:MED)
It's not a stretch to say that Medartis Holding AG's ( VTX:MED ) price-to-sales (or "P/S") ratio of 5.2x right now...Analysis Article • Jan 31
Medartis Holding (VTX:MED) May Have Issues Allocating Its Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Analysis Article • Oct 30
Why Medartis Holding AG (VTX:MED) Could Be Worth Watching
Medartis Holding AG ( VTX:MED ), might not be a large cap stock, but it received a lot of attention from a substantial...Analysis Article • Sep 07
These Analysts Think Medartis Holding AG's (VTX:MED) Sales Are Under Threat
Market forces rained on the parade of Medartis Holding AG ( VTX:MED ) shareholders today, when the analysts downgraded...Analysis Article • Jul 29
When Should You Buy Medartis Holding AG (VTX:MED)?
Medartis Holding AG ( VTX:MED ), is not the largest company out there, but it saw a decent share price growth in the...Analysis Article • May 06
Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analysis Article • Feb 08
At CHF123, Is It Time To Put Medartis Holding AG (VTX:MED) On Your Watch List?
Medartis Holding AG ( VTX:MED ), is not the largest company out there, but it saw a decent share price growth in the...Analysis Article • Jan 18
Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Nov 10
We Think Medartis Holding (VTX:MED) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Sep 29
Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Analysis Article • Jun 08
Some Investors May Be Worried About Medartis Holding's (VTX:MED) Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...Analysis Article • Mar 16
How Much Of Medartis Holding AG (VTX:MED) Do Insiders Own?
A look at the shareholders of Medartis Holding AG ( VTX:MED ) can tell us which group is most powerful. Institutions...Shareholder Returns
| MED | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | 0.5% | 1.4% | 1.1% |
| 1Y | 11.4% | -7.9% | 18.8% |
Return vs Industry: MED exceeded the Swiss Medical Equipment industry which returned -7.9% over the past year.
Return vs Market: MED underperformed the Swiss Market which returned 18.8% over the past year.
Price Volatility
| MED volatility | |
|---|---|
| MED Average Weekly Movement | 4.6% |
| Medical Equipment Industry Average Movement | 4.1% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in CH Market | 7.7% |
| 10% least volatile stocks in CH Market | 2.2% |
Stable Share Price: MED has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: MED's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 1,259 | Matthias Schupp | www.medartis.com |
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide. The company’s medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. It provides products for the hand, wrist, forearm, elbow, shoulder, and foot and ankle, as well as for upper and lower extremities, mandible, midface, orthognathic under the APTUS and MODUS names, as well as CMX services through web portal, and kerimedical products.
Medartis Holding AG Fundamentals Summary
| MED fundamental statistics | |
|---|---|
| Market cap | CHF 1.10b |
| Earnings (TTM) | CHF 8.35m |
| Revenue (TTM) | CHF 269.26m |
131.5x
P/E Ratio4.1x
P/S RatioIs MED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MED income statement (TTM) | |
|---|---|
| Revenue | CHF 269.26m |
| Cost of Revenue | CHF 64.93m |
| Gross Profit | CHF 204.33m |
| Other Expenses | CHF 195.98m |
| Earnings | CHF 8.35m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 18, 2026
| Earnings per share (EPS) | 0.67 |
| Gross Margin | 75.89% |
| Net Profit Margin | 3.10% |
| Debt/Equity Ratio | 47.3% |
How did MED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/07 01:55 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medartis Holding AG is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Research Partners AG |
| Ilya Burgansky | Research Partners AG |
| Alexander Burgansky | Research Partners AG |